2Johnson B J, Estrada I, Shen Z, et al. Differential gene expression in response to adjunctive recombinant human interleukin-2 immunotherapy in multidrug-resistant tuberculosis patients. Infect Immun, 1998 ;66(6) :2426
5Shiratsuchi H, Okuda Y, Tsuyuguchi I. Recombinant human interleukin-2 reverses in vitro - deficient cell-mediated immune responses to tuberculin purified protein derivative by lymphocytes of tuberculous patients. Infect Immun,1987 Sep, 55(9): 2126
6Johnson B J, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low - dose IL-2 and multidrug therapy. Cytokines Mol Ther,1995 Sep; 1(3): 185
7Johnson B J, Bekker LG, Rickman R, et al. rhuIL-2 adjunctive therapy in multidrug resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis,1997; 78 (3 ～4): 195
9Shiratsuchi H, et al. Recombinant human interleukin-2 reveres in vitrodeficient cell - mediated immune responses to tuberculosis purrified protein derivative by lymphocytes of tuberculosis patients. Infect Immun,1987; 55:2126
3Johnson BJ, Ress SR, Willcox P, et al. Clinical and immune responses of tuberculosis patients treated with low-dos IL-2 and multidrug therapy. Cytokines Mol Ther, 1995, 1(3) : 185-196.
4Johnson B J, Bekker LG, Rickman R, et al. rhulL-2 adjunctive therapy in multidrug-resistant tuberculosis: a comparison of two treatment regimens and placebo. Tuber Lung Dis,1997,78 (3-4): 195-203.
5Aviles Ingles MJ, Contessotto C, Ontanon Rodrignez J, et al. Serum soluble interleukin-2 receptor. A useful indicator of the clinical course in pulmonary tuberculosis. Tuber Lung Dis, 1995,76(2) : 130-135.
